Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NeuroPace IncNPCE · Entity 5459 | Director · Chief Executive Officer | February 21, 2023 | February 22, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NeuroPace Inc
Report date February 21, 2023 · Filed February 22, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 407,080 |
Reported balance
After 2023-02-21 transaction · row 1
1 source rowRow 1 · 2023-02-21 · Grant · Acquired 225,000 · Balance 407,080 F1: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement. 25% of the RSUs vest on February 21, 2024 and the remaining RSUs vest in eight (8) equal quarterly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement. 25% of the RSUs vest on February 21, 2024 and the remaining RSUs vest in eight (8) equal quarterly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 21, 2023 Filed Feb 22, 2023 19:38 UTC | NeuroPace Inc NPCE · Entity 5459 | GrantCommon Stock | 225,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-011945 · doc4.xml · nonDerivative · entry 1 Favet Michael · CIK 0001855656 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 407,080 F1 · shares: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement. 25% of the RSUs vest on February 21, 2024 and the remaining RSUs vest in eight (8) equal quarterly installments thereafter. Read SEC document |
| March 08, 2022 Filed Mar 8, 2022 16:43 UTC | NeuroPace Inc NPCE · Entity 5459 | GrantStock Option (Right to Buy) · Derivative | 310,160 | $0.00 Strike: $8.10 | $0.00 |
DisclosureSEC source: 0001209191-22-017119 · doc4.xml · derivative · entry 2 Favet Michael · CIK 0001855656 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,160 Underlying: Common Stock · 310,160 shares Expires 2032-03-07 F2 · derivative.exercise_date: 25% of the shares subject to the option vest on March 8, 2023. The remaining shares subject to the option vest in thirty six (36) equal consecutive monthly installments thereafter. The option is early exercisable. Read SEC document |
| March 08, 2022 Filed Mar 8, 2022 16:43 UTC | NeuroPace Inc NPCE · Entity 5459 | GrantCommon Stock | 155,080 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-017119 · doc4.xml · nonDerivative · entry 1 Favet Michael · CIK 0001855656 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,080 F1 · shares: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement. 25% of the RSUs vest on March 8, 2023 and the remaining RSUs vest in twelve (12) equal quarterly installments thereafter. Read SEC document |
| June 04, 2021 Filed Jun 8, 2021 18:04 UTC | NeuroPace Inc NPCE · Entity 5459 | GrantStock Option (Right to Buy) · Derivative | 53,180 | $0.00 Strike: $21.67 | $0.00 |
DisclosureSEC source: 0001209191-21-038994 · doc4.xml · derivative · entry 3 Favet Michael · CIK 0001855656 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,180 Underlying: Common Stock · 53,180 shares Expires 2031-06-03 F3 · derivative.exercise_date: 25% of the shares subject to the option vest on April 22, 2022. The remaining shares subject to the option vest in twelve (12) equal quarterly installments thereafter. The option is early exercisable. Read SEC document |
| June 04, 2021 Filed Jun 8, 2021 18:04 UTC | NeuroPace Inc NPCE · Entity 5459 | GrantCommon Stock | 26,590 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-038994 · doc4.xml · nonDerivative · entry 1 Favet Michael · CIK 0001855656 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,590 F1 · shares: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement. 25% of the RSUs vest on April 22, 2022 and the remaining RSUs vest in twelve (12) equal quarterly installments thereafter. Read SEC document |
| June 04, 2021 Filed Jun 29, 2021 18:12 UTC Amendment | NeuroPace Inc NPCE · Entity 5459 | GrantStock Option (Right to Buy) · Derivative | 54,000 | $0.00 Strike: $21.67 | $0.00 |
DisclosureSEC source: 0001209191-21-043744 · doc4a.xml · derivative · entry 2 Favet Michael · CIK 0001855656 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,000 Underlying: Common Stock · 54,000 shares Expires 2031-06-03 F2 · derivative.exercise_date: 25% of the shares subject to the option vest on April 22, 2022. The remaining shares subject to the option vest in twelve (12) equal quarterly installments thereafter. The option is early exercisable. Read SEC document |
| June 04, 2021 Filed Jun 29, 2021 18:12 UTC Amendment | NeuroPace Inc NPCE · Entity 5459 | GrantCommon Stock | 27,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-043744 · doc4a.xml · nonDerivative · entry 1 Favet Michael · CIK 0001855656 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,000 F1 · shares: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement. 25% of the RSUs vest on April 22, 2022 and the remaining RSUs vest in twelve (12) equal quarterly installments thereafter. Read SEC document |
| April 26, 2021 Filed Apr 26, 2021 17:16 UTC | NeuroPace Inc NPCE · Entity 5459 | ConversionSeries B' Preferred Stock · Derivative | 7,219 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-028324 · doc4.xml · derivative · entry 4 Favet Michael · CIK 0001855656 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 7,219 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Each share of Preferred Stock automatically converted on a 1-for-1 basis into Common Stock at any time upon the closing of the Issuer's initial public offering, for no additional consideration. The Preferred Stock has no expiration date. F2 · derivative.expiration_date: Each share of Preferred Stock automatically converted on a 1-for-1 basis into Common Stock at any time upon the closing of the Issuer's initial public offering, for no additional consideration. The Preferred Stock has no expiration date. F1 · ownership.nature: Shares are held by the Favet Living Trust, of which the Reporting Person and the Reporting Person's spouse serve as co-trustees. Read SEC document |
| April 26, 2021 Filed Apr 26, 2021 17:16 UTC | NeuroPace Inc NPCE · Entity 5459 | ConversionSeries A' Preferred Stock · Derivative | 343 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-028324 · doc4.xml · derivative · entry 3 Favet Michael · CIK 0001855656 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 343 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Each share of Preferred Stock automatically converted on a 1-for-1 basis into Common Stock at any time upon the closing of the Issuer's initial public offering, for no additional consideration. The Preferred Stock has no expiration date. F2 · derivative.expiration_date: Each share of Preferred Stock automatically converted on a 1-for-1 basis into Common Stock at any time upon the closing of the Issuer's initial public offering, for no additional consideration. The Preferred Stock has no expiration date. F1 · ownership.nature: Shares are held by the Favet Living Trust, of which the Reporting Person and the Reporting Person's spouse serve as co-trustees. Read SEC document |
| April 26, 2021 Filed Apr 26, 2021 17:16 UTC | NeuroPace Inc NPCE · Entity 5459 | GrantCommon Stock | 15,385 | $0.03 | $461.55 |
DisclosureSEC source: 0001209191-21-028324 · doc4.xml · nonDerivative · entry 2 Favet Michael · CIK 0001855656 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 22,947 F1 · shares: Shares are held by the Favet Living Trust, of which the Reporting Person and the Reporting Person's spouse serve as co-trustees. F1 · ownership.nature: Shares are held by the Favet Living Trust, of which the Reporting Person and the Reporting Person's spouse serve as co-trustees. Read SEC document |
| April 26, 2021 Filed Apr 26, 2021 17:16 UTC | NeuroPace Inc NPCE · Entity 5459 | ConversionCommon Stock | 7,562 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-028324 · doc4.xml · nonDerivative · entry 1 Favet Michael · CIK 0001855656 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,562 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares are held by the Favet Living Trust, of which the Reporting Person and the Reporting Person's spouse serve as co-trustees. F1 · ownership.nature: Shares are held by the Favet Living Trust, of which the Reporting Person and the Reporting Person's spouse serve as co-trustees. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.